Drugs / BMS-962212
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT03197779 | Nov 2013 → Feb 2016 | thrombotic disease | Bristol-Myers Squibb | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | BMS-962212 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03197779 ↗ |
| Modality | Small molecule | — CHEMBL4073292 ↗ |
| Route | Intravenous | “Intravenous Infusion administration over 2 hours or 5 days” NCT03197779 ↗ |